InternationalUSRemember you can easily switch between MIP US and MIP International at any time

In-house roundup: Clearer Section 112 revisions wanted; orphan drug exclusivity not enough; Commission says SPC waiver benefits all; Article 3d wording examined



Patrick Wingrove, London


Managing IP rounds up the latest news and analysis from patent-focused businesses

Money

Section 112 revision must be clearer and future-proof say stakeholders

Counsel from Novartis, Fallbrook Technologies, InterDigital and the Software and Information Industry Association reveal how they would like to see reform to written description requirements handled in the US. Read More... 

Market exclusivity not right protection to incentivise orphan drug development

With small patient pools and high investment costs, pharmaceutical companies say more incentives are needed to investigate pre-existing drugs and bring about research into rare diseases. Read more... 

SPC waiver benefits all manufacturers says European Commission officer

Alfonso Callez-Sanchez explains the reasoning behind the waiver proposal, including how it was intended to benefit the entire pharmaceutical industry and spur competitiveness in the EU. Read more... 

An industry exploration of the Article 3d wording

Counsel from Valneva, Confo Therapeutics and Lazewski Depo & Partners questioned the literal and teleological interpretations of Article 3d of the SPC Regulation at the Patent Term Extension conference in Munich. Read more... 


Comments






More from the Managing IP blog


null null null

nullnullnull

null

May / June 2019

From trademarks to trade secrets: in-house tips on brand protection in China

Despite the well-known struggles in protecting trademarks and trade secrets in China, there are some tried-and-tested strategies to employ, as Karry Lai and Ellie Mertens hear from in-house counsel at a range of domestic and international companies



Most read articles

Supplements